이탈리아의 심혈관 기기 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the Italy cardiovascular devices market size is expected to grow from USD 1.9 billion in 2025 to USD 2.01 billion in 2026 and is forecast to reach USD 2.66 billion by 2031 at 5.75% CAGR over 2026-2031.

This report is Segmented by Device Type (Diagnostic & Monitoring Devices and Therapeutic & Surgical Devices), by Indication (Coronary Artery Disease, Arrhythmia and More), by End User (Hospitals, Home Care Settings and More). The Report Offers the Value (in USD Million) for the Above Segments. The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Italy Cardiovascular Devices Market Trends and Insights

National Screening Programs & Rising Coronary Angiography Volumes

Italy's structured cardiovascular screening is uncovering previously undetected conditions in both athletes and the elderly, generating steady demand for diagnostic imaging and catheter-based tools. Coronary angiography volumes that dipped during the pandemic have returned to pre-crisis levels, with urgent post-surgical angiography now required in 1.83% of cardiac surgery cases. These patterns are stimulating investment in fractional flow reserve, optical coherence tomography and AI-enabled echocardiography platforms that improve lesion assessment and shorten procedure times. The Italian cardiovascular devices market benefits as hospital cath-lab managers refresh inventories to accommodate both routine and emergency cases.

Government Incentives for Early TAVI Reimbursement under LEA

The listing of Transcatheter Aortic Valve Implantation in the Essential Levels of Assistance has cut the median inpatient stay from 7 to 5 days, saving hospitals USD 565 per patient while broadening patient eligibility. Favorable funding, paired with Italy's high-risk patient profile, is advancing uptake of next-generation self-expanding and balloon-expandable valves. Device makers are responding with low-profile delivery systems and durability-enhanced leaflet materials, reinforcing momentum in the Italian cardiovascular devices market.

National Consip Price Caps Compressing ASPs for Stents & TAVI

Italian procurement authority Consip imposes ceiling prices that have narrowed margins on drug-eluting stents and valve implants. A 2024 tender awarded to a new entrant underscored intensifying competition and price pressure in TAVI. Hospitals, reimbursed via diagnosis-related groups, increasingly look for bundled-service offers that link device supply to clinical outcomes. Manufacturers must therefore justify performance with head-to-head evidence while revising contracting terms, dampening immediate revenue growth in the Italian cardiovascular devices market.

Other drivers and restraints analyzed in the detailed report include:

1. Aging Population-Driven Surge in Peripheral Artery Disease Procedures
2. Rapid Technological Advancements and Minimally Invasive Procedures
3. EU-MDR Re-certification Delays Causing Catheter Supply Shortages

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutic and surgical devices command 57.65% of the Italian cardiovascular devices market, anchored by sustained implant volumes for drug-eluting stents, cardiac rhythm management systems and Transcatheter Aortic Valve Implantation. The Italian cardiovascular devices market size for therapeutic systems is projected to expand at 5.33% CAGR, supported by hospital upgrades and aging-driven procedure counts. Demand tilts toward platforms that shorten procedure time, such as rapid-exchange angioplasty balloons and single-access vascular closure devices, which improve throughput in busy cath labs.

Diagnostic and monitoring solutions, despite a smaller base, are forecast to rise at a 5.98% CAGR. Fractional flow reserve consoles, ECG-gated CT scanners and AI-powered echocardiography suites are seeing the fastest growth as physicians seek functional data to refine treatment plans. Portable Holter monitors and insertable cardiac monitors with six-year battery life further broaden remote-care capabilities.

Complete Report Scope:

• By Device
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitor
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS/OCT Catheters
    • Cardiac Rhythm Management
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR/TAVI
      • Mechanical Valves
      • Tissue/Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Indication
  • Coronary Artery Disease
  • Arrhythmia
  • Heart Failure
  • Valvular Heart Disease
• By End User
  • Hospitals
  • Home care Settings
  • Others

List of Companies Covered in this Report:

1. Medtronic
2. Abbott Laboratories
3. Boston Scientific
4. Edward Lifesciences
5. Terumo
6. LivaNova
7. BIOTRONIK
8. Koninklijke Philips
9. Siemens Healthineers
10. GE HealthCare Technologies Inc.
11. Merit Medical Systems
12. Cook Group
13. B. Braun
14. Cardinal Health Inc. (Cordis)
15. Johnson & Johnson MedTech (Biosense Webster)
16. MicroPort Scientific Corp.
17. Getinge
18. Shockwave Medical Inc.
19. W. L. Gore & Associates
20. Lepu Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 National Screening Programs & Rising Coronary Angiography Volumes
  • 4.2.2 Government Incentives for Early TAVI Reimbursement under LEA
  • 4.2.3 Aging Population-Driven Surge in Peripheral Artery Disease (PAD) Procedures
  • 4.2.4 Expansion of Public-Private Cardiovascular Centers
  • 4.2.5 Post-COVID Backlog of Elective Cardiac Surgeries Accelerating PCI Adoption
  • 4.2.6 Increasing Adoption of Minimally Invasive Cardiac Procedures
• 4.3 Market Restraints
  • 4.3.1 National Consip Price Caps Compressing ASPs for Stents & TAVI
  • 4.3.2 EU-MDR Re-certification Delays Causing Catheter Supply Shortages
  • 4.3.3 Regional Disparities in Device Access Across Public Hospitals
  • 4.3.4 Budgetary Constraints in Public Healthcare Spending
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory & Technological Outlook
• 4.6 Porters Five Forces Analysis
  • 4.6.1 Bargaining Power of Suppliers
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Threat of New Entrants
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Device
  • 5.1.1 Diagnostic & Monitoring Devices
    • 5.1.1.1 ECG Systems
    • 5.1.1.2 Remote Cardiac Monitor
    • 5.1.1.3 Cardiac MRI
    • 5.1.1.4 Cardiac CT
    • 5.1.1.5 Echocardiography / Ultrasound
    • 5.1.1.6 Fractional Flow Reserve (FFR) Systems
  • 5.1.2 Therapeutic & Surgical Devices
    • 5.1.2.1 Coronary Stents
      • 5.1.2.1.1 Drug-Eluting Stents
      • 5.1.2.1.2 Bare-Metal Stents
      • 5.1.2.1.3 Bioresorbable Stents
    • 5.1.2.2 Catheters
      • 5.1.2.2.1 PTCA Balloon Catheters
      • 5.1.2.2.2 IVUS/OCT Catheters
    • 5.1.2.3 Cardiac Rhythm Management
      • 5.1.2.3.1 Pacemakers
      • 5.1.2.3.2 Implantable Cardioverter Defibrillators
      • 5.1.2.3.3 Cardiac Resynchronization Therapy Devices
    • 5.1.2.4 Heart Valves
      • 5.1.2.4.1 TAVR/TAVI
      • 5.1.2.4.2 Mechanical Valves
      • 5.1.2.4.3 Tissue/Bioprosthetic Valves
    • 5.1.2.5 Ventricular Assist Devices
    • 5.1.2.6 Artificial Hearts
    • 5.1.2.7 Grafts & Patches
    • 5.1.2.8 Other Cardiovascular Surgical Devices
• 5.2 By Indication
  • 5.2.1 Coronary Artery Disease
  • 5.2.2 Arrhythmia
  • 5.2.3 Heart Failure
  • 5.2.4 Valvular Heart Disease
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Home care Settings
  • 5.3.3 Others

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Medtronic plc
  • 6.4.2 Abbott Laboratories
  • 6.4.3 Boston Scientific Corporation
  • 6.4.4 Edwards Lifesciences Corporation
  • 6.4.5 Terumo Corporation
  • 6.4.6 LivaNova PLC
  • 6.4.7 Biotronik SE & Co. KG
  • 6.4.8 Philips Healthcare
  • 6.4.9 Siemens Healthineers AG
  • 6.4.10 GE HealthCare Technologies Inc.
  • 6.4.11 Merit Medical Systems Inc.
  • 6.4.12 Cook Medical LLC
  • 6.4.13 B. Braun Melsungen AG
  • 6.4.14 Cardinal Health Inc. (Cordis)
  • 6.4.15 Johnson & Johnson MedTech (Biosense Webster)
  • 6.4.16 MicroPort Scientific Corp.
  • 6.4.17 Getinge AB
  • 6.4.18 Shockwave Medical Inc.
  • 6.4.19 W. L. Gore & Associates
  • 6.4.20 Lepu Medical Technology

7 Market Opportunities & Future Outlook